BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent.
Bioaffinity Technologies Inc. (BIAF)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 24,413 | $93,500 | 0% | |
| 2. | 19,850 | $6,551 | -16% | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 8,163 | $0.00 | 22,448 | 2022-08-31 | Filing | |
| $0.00 | 4,081 | $0.00 | 4,081 | 2022-08-31 | Filing | |
| $0.00 | 4,081 | $0.00 | 4,081 | 2022-08-31 | Filing | |
| $0.00 | 2,448 | $0.00 | 30,323 | 2022-09-01 | Filing | |
| $0.00 | 16,326 | $0.00 | 19,897 | 2022-08-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 55,543 | $212,730 | 0% | |
| 2. | 48,293 | $184,961 | 0% | |
| 3. | 42,600 | $164,010 | 0% | |
| 4. | 31,071 | $119,002 | 0% | |
| 5. | 14,386 | $55,098 | 0% |
News See All
Hedge Fund Resource Center